Summary: Lancaster University researchers report a drug developed to treat diabetes shows promise in reversing memory loss associated with Alzheimer’s in mouse models of the disease. The drug appears to have a neuroprotective effect, enhancing brain growth factors while reducing amyloid plaques, chronic inflammation and oxidative stress. The drug also slows down the rate of neuron loss.
Source: Lancaster University.
A drug developed for diabetes could be used to treat Alzheimer’s after scientists found it “significantly reversed memory loss” in mice through a triple method of action.
The research, published in Brain Research, could bring substantial improvements in the treatment of Alzheimer’s disease through the use of a drug originally created to treat type 2 diabetes.
Lead researcher Professor Christian Holscher of Lancaster University in the UK said the novel treatment “holds clear promise of being developed into a new treatment for chronic neurodegenerative disorders such as Alzheimer’s disease.”
Alzheimer’s disease is the most common cause of dementia and the numbers are expected to rise to two million people in the UK by 2051 according to Alzheimer’s Society, who part- funded the research.
Dr Doug Brown, Director of Research and Development at Alzheimer’s Society, said: “”With no new treatments in nearly 15 years, we need to find new ways of tackling Alzheimer’s. It’s imperative that we explore whether drugs developed to treat other conditions can benefit people with Alzheimer’s and other forms of dementia. This approach to research could make it much quicker to get promising new drugs to the people who need them.”
Although the benefits of these ‘triple agonist’ drugs have so far only been found in mice, other studies with existing diabetes drugs such as liraglutide have shown real promise for people with Alzheimer’s, so further development of this work is crucial.”
This is the first time that a triple receptor drug has been used which acts in multiple ways to protect the brain from degeneration. It combines GLP-1, GIP and Glucagon which are all growth factors. Problems with growth factor signalling have been shown to be impaired in the brains of Alzheimer’s patients.
The study used APP/PS1 mice, which are transgenic mice that express human mutated genes that cause Alzheimer’s. Those genes have been found in people who have a form of Alzheimer’s that can be inherited. Aged transgenic mice in the advanced stages of neurodegeneration were treated.
In a maze test, learning and memory formation were much improved by the drug which also:-
enhanced levels of a brain growth factor which protects nerve cell functioning
reduced the amount of amyloid plaques in the brain linked with Alzheimer’s
reduced both chronic inflammation and oxidative stress slowed down the rate of nerve cell loss
Professor Holscher said: “These very promising outcomes demonstrate the efficacy of these novel multiple receptor drugs that originally were developed to treat type 2 diabetes but have shown consistent neuro- protective effects in several studies.”
“Clinical studies with an older version of this drug type already showed very promising results in people with Alzheimer’s disease or with mood disorders”
“Here we show that a novel triple receptor drug shows promise as a potential treatment for Alzheimer’s but further dose-response tests and direct comparisons with other drugs have to be conducted in order to evaluate if this new drugs is superior to previous ones.”
Type 2 diabetes is a risk factor for Alzheimer’s and has been implicated in the progression of the disease. Impaired insulin has been linked to cerebral degenerative processes in type 2 diabetes and Alzheimer’s disease. Insulin desensitisation has also been observed in the Alzheimer’s disease brain. The desensitisation could play a role in the development of neurodegenerative disorders as insulin is a growth factor with neuroprotective properties.
About this neuroscience research article
Source: Gillian Whitworth – Lancaster University Publisher: Organized by NeuroscienceNews.com. Image Source: NeuroscienceNews.com image is credited to Lancaster University. Original Research: Full open access research for “Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer’s disease” by Jingjing Tai, Weizhen Liu, Yanwei Li, Lin Lin and Christian Hölscher in Brain Research. Published online October 16 2017 doi:10.1016/j.brainres.2017.10.012
Cite This NeuroscienceNews.com Article
[cbtabs][cbtab title=”MLA”]Lancaster University “Diabetes Drug ‘Significantly Reverses Memory Loss’ in Alzheimer’s: Mouse Study.” NeuroscienceNews. NeuroscienceNews, 2 January 2018. <https://neurosciencenews.com/alzheimers-diabetes-memory-8251/>.[/cbtab][cbtab title=”APA”]Lancaster University (2018, January 2). Diabetes Drug ‘Significantly Reverses Memory Loss’ in Alzheimer’s: Mouse Study. NeuroscienceNews. Retrieved January 2, 2018 from https://neurosciencenews.com/alzheimers-diabetes-memory-8251/[/cbtab][cbtab title=”Chicago”]Lancaster University “Diabetes Drug ‘Significantly Reverses Memory Loss’ in Alzheimer’s: Mouse Study.” https://neurosciencenews.com/alzheimers-diabetes-memory-8251/ (accessed January 2, 2018).[/cbtab][/cbtabs]
Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer’s disease
Type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer disease (AD). Previous studies have shown that the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) that have anti-diabetic properties show very promising effects in animal models of AD. Glucagon (Gcg) is a hormone and growth-factor, and the Gcg receptor is expressed in the brain. Here we test the effects of a triple receptor agonist (TA), which activates GIP-1, GIP and glucagon receptors at the same time. In the present study, the effects of the TA were evaluated in the APP/PS1 transgenic mouse model of AD. The TA was injected once-daily (10 nmol/kg i.p.) for two months. The results showed that treatment with TA significantly reversed the memory deficit in the APP/PS1 mice in a spatial water maze test. Moreover, the drug reduced levels of the mitochondrial pro-apoptotic signaling molecule BAX, increased the anti-apoptotic signaling molecule Bcl-2 and enhanced the levels of BDNF, a key growth factor that protects synaptic function. Levels of synaptophysin were enhanced, demonstrating protection from synaptic loss that is observed in AD. Neurogenesis in the dentate gyrus was furthermore enhanced as shown in the increase of doublecortin positive cells. Furthermore, TA treatment reduced the total amount of β-amyloid, reduced neuroinflammation (activated microglia and astrocytes), and oxidative stress in the cortex and hippocampus. Thus, these findings show that novel TAs are a promising lead for the design of future treatment strategies in AD.
“Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer’s disease” by Jingjing Tai, Weizhen Liu, Yanwei Li, Lin Lin and Christian Hölscher in Brain Research. Published online October 16 2017 doi:10.1016/j.brainres.2017.10.012